Andrea Wright

Dr. Andrea Wright

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2022 in Journal of Small Animal Practice
Verified
Journal Article
Open access
AWAndrea Wright
Andrea Wright
DAD. M. Amodie
D. M. Amodie
NCN. Cernicchiaro
N. Cernicchiaro
BLB. D. X. Lascelles
B. D. X. Lascelles
APA. M. Pavlock
A. M. Pavlock
DBD. J. Bartram
D. J. Bartram
Objectives: To investigate the diagnostic value of an owner‐completed canine osteoarthritis screening checklist to help identify previously undiagnosed osteoarthritis cases, and assess their response to carprofen treatment by monitoring pain and functional mobility.Materials and Methods: Dogs (n=500) whose owners reported ≥1 positive response to the osteoarthritis checklist were examined to identify dogs with previously undiagnosed osteoarthritis. Eligible dogs (n=133) were evaluated for pain and video mobility analysis by Helsinki Chronic Pain Index and visual analogue scale scores, respectively, following carprofen treatment, administered for 30 days (n=95) or up to 120 days (n=38). Dogs were filmed at clinics performing activities (walking, jogging, sitting/lying, walking up and down stairs), and scored at days 0, 30 and 120 using visual analogue scale by an independent blinded expert.Results: A diagnosis of osteoarthritis was confirmed by a veterinarian in 38% (188 of 500) of dogs. Balance of sensitivity and specificity across the original group of nine screening questions was optimised to approximately 88 and 71%, respectively, after elimination of three questions. Pain measured by Helsinki Chronic Pain Index and functional mobility improved over time in response to treatment with carprofen. Mean ability scores for activities significantly improved between days 0 and 30 for walking, jogging, sitting/lying and walking down stairs, and days 0 and 120 for sitting/lying and walking up stairs.Clinical Significance: More osteoarthritis cases were identified in study dogs than previous prevalence estimates, indicating the screening checklist's potential to help identify for further evaluation cases that could otherwise remain undiagnosed. Improvements in function were demonstrated after carprofen treatment.

18 November 2021 in Frontiers in Veterinary Science
Verified
Journal Article
Open access
GYGillian Yeowell
Gillian Yeowell
DBDanielle Burns
Danielle Burns
FFFrancis Fatoye
Francis Fatoye
TGTadesse Gebrye
Tadesse Gebrye
AWAndrea Wright
Andrea Wright
IOIsaac Odeyemi
Isaac Odeyemi
Objectives: The assessment of health-related quality of life (HRQoL) is becoming increasingly important in companion animals. This study describes a systematic review and development of a proposed conceptual framework to assess HRQoL in cats with osteoarthritis (OA).Methods: The conceptual framework was developed according to published guidelines. A comprehensive search of the CAB Direct, Scopus, PubMed, and Web of Science databases was carried out for publications in English from inception to November 12, 2019. Search words used were “cat”, “feline”, “chronic pain”, “pain”, and “quality of life”. Publications were selected if they were full-text and peer-reviewed, based on primary data, and identified or measured behavioral symptoms of chronic musculoskeletal pain in cats. A systematic review was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A data extraction form was developed from categories identified in the literature review and piloted on a small number of studies to ascertain the appropriateness for relevant data extraction. Categories were then finalized, and key domains were identified. The domains were then synthesized to develop a conceptual framework.Results: A total of 454 studies were identified, of which 14 met the eligibility criteria and were included in the meta-synthesis. All 14 were assessed to be of good quality. Seven domains related to HRQoL in cats with OA were thematically identified from the data: mobility, physical appearance, energy and vitality, mood, pain expression, sociability, and physical and mental wellbeing. The three main HRQoL domains were pain expression, mobility, and physical and mental wellbeing, which impacted all the others. Pain and mobility impacted all six other domains, with increased pain and decreased mobility negatively impacting physical appearance, energy and vitality, mood, sociability, and physical and mental wellbeing.Conclusions and Relevance: This is the first study to develop an evidence-based conceptual framework for the assessment of HRQoL in cats with OA. The proposed conceptual framework suggests that effective management of chronic pain in cats may improve their overall HRQoL.

21 November 2024 in Animals
Verified
Journal Article
Open access
PDF file
CDCHRISTOS DADOUSIS
CHRISTOS DADOUSIS
AWAnthony David Whetton
Anthony David Whetton
KMKennedy Mwacalimba
Kennedy Mwacalimba
AMAlexandre Merlo
Alexandre Merlo
AWAndrea Wright
Andrea Wright
NGNophar Geifman
Nophar Geifman
Chronic kidney disease (CKD) is characterised by progressive kidney damage and encompasses a broad range of renal pathologies and aetiologies. In humans, CKD is an increasing global health problem, in particular in the western world, while in cats and dogs, CKD is one of the leading causes of mortality and morbidity. Here, we aimed to develop an enhanced understanding of the knowledge base related to the pathophysiology of renal disease and CKD in cats and dogs. To achieve this, we leveraged a text-mining approach for reviewing trends in the literature and compared the findings to evidence collected from publications related to CKD in humans. Applying a quantitative text-mining technique, we examined data on clinical signs, diseases, clinical and lab methods, cell types, cytokine, and tissue associations (co-occurrences) captured in PubMed biomedical literature. Further, we examined different types of pain within human CKD-related publications, as publications on this topic are sparser in companion animals, but with the growing importance of animal welfare and quality of life, it is an area of interest. Our findings could serve as substance for future research studies. The systematic automated review of relevant literature, along with comparative analysis, has the potential to summarise scientific evidence and trends in a quick, easy, and cost-effective way. Using this approach, we identified targeted and novel areas of investigation for renal disease in cats and dogs.

19 March 2024 in Animals
Verified
Journal Article
Open access
PDF file
AWAndrea Wright
Andrea Wright
AHAndrew Hillier
Andrew Hillier
JLJonathan Lambert
Jonathan Lambert
KMKennedy Mwacalimba
Kennedy Mwacalimba
NLNatalie Raquel Lloyd
Natalie Raquel Lloyd
RWRobin Wyn
Robin Wyn
Oclacitinib is an oral therapy indicated for pruritus associated with allergic or atopic dermatitis in dogs. This study sought to assess pet owners’ perceptions of the relative convenience and value of the conventional film-coated formulation and the chewable formulation. A quantitative discrete-choice experimental methodology was applied, comparing (conventional, film-coated) oclacitinib versus chewable oclacitinib using unbranded treatment profiles. Initially, a qualitative interview phase with pet owners and veterinarians was conducted to develop detailed treatment profiles. Subsequently, pet owners participated in a quantitative survey. Overall, 1590 pet owners provided survey responses. Most respondents (62%) reported having experienced challenges administering tablet-based therapies to their dog(s). Half of all respondents (52%) had experience administering flavoured or chewable tablets to their dog. Comparing oclacitinib and chewable oclacitinib (with or without associated costs), the majority of the respondents preferred the chewable formulation in all regions across short-term and long-term scenarios (≥58%; all p < 0.05). The current research is one of few survey-driven studies for treatment preferences in companion animal medicine. Veterinarians may offer chewable or palatable treatment options where available, with potential positive impacts on convenience, compliance, outcomes, quality of life, and the human–animal bond.

15 February 2024 in Veterinary Dermatology
Verified
Journal Article
Closed access
JWJ. R. Wells
J. R. Wells
AHA. Hillier
A. Hillier
RHR. Holland
R. Holland
KMK. Mwacalimba
K. Mwacalimba
CNchiara noli
chiara noli
AWAndrea Wright
Andrea Wright

6 July 2025 in Animals
Verified
Journal Article
Open access
PDF file
CTConstantina N. Tsokana
Constantina N. Tsokana
George ValiakosGeorge Valiakos
George Valiakos
KMKennedy Mwacalimba
Kennedy Mwacalimba
DRDanielle Riley
Danielle Riley
AEAshley Enstone
Ashley Enstone
AWAndrea Wright
Andrea Wright
Cat owners are involved in their cats’ healthcare, including the prevention of parasitic diseases. However, a comprehensive understanding of their preferences for feline antiparasitics is lacking. This study addresses this gap through a multifaceted methodology comprising three phases. In Phase 1, the physical properties and usability aspects of seven topical antiparasitic formulations were assessed. Within Phase 2, an ease-of-use study was conducted to evaluate the cat owners’ application experience with deidentified products representing three topical antiparasitics. Phase 3 included the identification and validation of product attributes most valued by pet owners through interviews with cat owners and veterinary experts. The product attributes identified informed the subsequent quantitative discrete choice experiment (DCE), which involved 1040 cat owners from different countries (Australia/New Zealand, Canada, Greece/Spain, and the UK) and aimed to analyze their preferences based on choices among product profiles mirroring four topical antiparasitics: selamectin–sarolaner, moxidectin–fluralaner, moxidectin–imidacloprid, and eprinomectin–esafoxolaner–praziquantel. Phase 1 showed that the selamectin–sarolaner formulation exhibits minimal odor, less stickiness, and less drying time. The ease-of-use study (Phase 2) showed that the blinded product representing the selamectin–sarolaner formulation was characterized by seamless application, rapid dispensing, and a sense of control during application. The quantitative DCE study (Phase 3) indicated a preference for the product profile mirroring the selamectin–sarolaner formulation among a global sample of cat owners. Demographic characteristics such as gender, age, and insurance status influenced their preferences. Key predictors for preferring the selamectin–sarolaner formulation over at least one comparator treatment included the ability to confirm successful administration, age restrictions, ease of application, and the time before the cat could sit on furniture following administration. These findings suggest that cat owners prioritize ease of use, safety, and overall user experience, providing valuable guidance for veterinary practitioners to make informed treatment recommendations.